These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1316 related items for PubMed ID: 11731664

  • 1. Sn-Mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah's Witness newborns as an alternative to exchange transfusion.
    Kappas A, Drummond GS, Munson DP, Marshall JR.
    Pediatrics; 2001 Dec; 108(6):1374-7. PubMed ID: 11731664
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin.
    Martinez JC, Garcia HO, Otheguy LE, Drummond GS, Kappas A.
    Pediatrics; 1999 Jan; 103(1):1-5. PubMed ID: 9917431
    [Abstract] [Full Text] [Related]

  • 4. A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns.
    Kappas A, Drummond GS, Valaes T.
    Pediatrics; 2001 Jul; 108(1):25-30. PubMed ID: 11433050
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin.
    Valaes T, Petmezaki S, Henschke C, Drummond GS, Kappas A.
    Pediatrics; 1994 Jan; 93(1):1-11. PubMed ID: 8265301
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Metalloporphyrins for treatment of unconjugated hyperbilirubinemia in neonates.
    Suresh GK, Martin CL, Soll RF.
    Cochrane Database Syst Rev; 2003 Jan; (2):CD004207. PubMed ID: 12804504
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia.
    Bhutani VK, Poland R, Meloy LD, Hegyi T, Fanaroff AA, Maisels MJ.
    J Perinatol; 2016 Jul; 36(7):533-9. PubMed ID: 26938918
    [Abstract] [Full Text] [Related]

  • 11. An early (sixth-hour) serum bilirubin measurement is useful in predicting the development of significant hyperbilirubinemia and severe ABO hemolytic disease in a selective high-risk population of newborns with ABO incompatibility.
    Sarici SU, Yurdakök M, Serdar MA, Oran O, Erdem G, Tekinalp G, Yiğit S.
    Pediatrics; 2002 Apr; 109(4):e53. PubMed ID: 11927726
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cochrane Review: Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants.
    Okwundu CI, Okoromah CA, Shah PS.
    Evid Based Child Health; 2013 Jan; 8(1):204-49. PubMed ID: 23878128
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Double phototherapy in jaundiced term infants with hemolysis.
    Thaithumyanon P, Visutiratmanee C.
    J Med Assoc Thai; 2002 Nov; 85(11):1176-81. PubMed ID: 12546314
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn.
    Miqdad AM, Abdelbasit OB, Shaheed MM, Seidahmed MZ, Abomelha AM, Arcala OP.
    J Matern Fetal Neonatal Med; 2004 Sep; 16(3):163-6. PubMed ID: 15590442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.